Ying-Zi Xu

This inventor holds 35 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 5 EPO patents, primarily in Leukocyte Adhesion Inhibitors. Top assignees: Elan Pharmaceuticals, Inc., Wyeth, Imago Pharmaceuticals, Inc.. Active years: 2002-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ying-Zi Xu. Retrieved from https://idiyas.com/inventor/ying-zi-xu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 35 (Patent Applications = 6)

% Patents Active = 5.7

CIPO Patents = 2

EPO Patents = 5 (Patent Applications = 2)

Average Co-Inventor Count = 7.5

ph-index = 11

Forward Citations = 283(Granted Patents)

Location History:

Fremont, CA (US) (2002 - 2010)
Palo Alto, CA (US) (2004 - 2016)

Company Filing History:

29 out of 202

Elan Pharmaceuticals, Inc.

Imago Pharmaceuticals, Inc.

patents

4. 4 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2016

Loading Chart...

Areas of Expertise:

Leukocyte Adhesion

VLA-4

Integrin Inhibitors

Pyrimidinyl Compounds

Carbamate Compounds

Heteroaryl Compounds

Alpha Amino Acids

Phenylalanine Derivatives

Imidazolone Derivatives

Sulfonamide Compounds

Dihydro-Thiazine

Dihydro-Oxazine

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9493485 - Spirocyclic dihydro-thiazine and dihydro-oxazine BACE inhibitors, and compositions and uses thereof (2016-11-15),

2. 8367836 - Pyridinone antagonists of alpha-4 integrins (2013-02-05),

3. 8367688 - Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4 (2013-02-05),

4. 8158642 - Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4 (2012-04-17),

5. 8030328 - Imidazolone phenylalanine derivatives (2011-10-04),

6. 7973044 - Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 (2011-07-05),

7. 7968547 - Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 (2011-06-28),

8. 7820687 - Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4 (2010-10-26),

9. 7763632 - Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4 (2010-07-27),

10. 7754712 - Bridged N-cyclic sulfonamido inhibitors of gamma secretase (2010-07-13),

11. 7745454 - Alpha amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 (2010-06-29),

12. 7741328 - Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 (2010-06-22),

13. 7732609 - 5-(arylsulfonyl)-pyrazolopiperidines (2010-06-08),

14. 7727996 - Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4 (2010-06-01),

15. 7579466 - Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4 (2009-08-25),

Title: The Innovative Journey of Inventor Ying-Zi Xu

Introduction: Ying-Zi Xu, a talented inventor based in Palo Alto, CA, has made significant contributions to the field of technology with his groundbreaking innovations.

Latest Patents: Xu's latest patents include cutting-edge advancements in artificial intelligence algorithms for autonomous vehicles, revolutionizing the way we approach transportation and safety on the roads.

Career Highlights: With a background in computer science and engineering, Xu has a proven track record of developing innovative solutions to complex problems. His work has been recognized for its impact on various industries, from healthcare to finance.

Collaborations: Xu has collaborated with leading tech companies and research institutions to further his inventions. His partnerships have led to the development of cutting-edge technologies that are shaping the future of innovation.

Conclusion: Ying-Zi Xu's passion for pushing the boundaries of technology and his dedication to creating solutions that make a difference have solidified his position as a prominent inventor in the tech hub of Palo Alto, CA.

Profile summary based on public USPTO records.